cysteine has been researched along with s-propargylcysteine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 21 (95.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, HR; Mu, Q; Rose, P; Wang, Q; Zhu, YZ | 1 |
| Gong, QH; Liu, XH; Pan, LL; Wang, Q; Xin, H; Zhu, YZ | 1 |
| Cai, W; Gu, Y; Liu, H; Ma, G; Shao, T; Yang, P; Zhang, L; Zhang, P; Zheng, Y; Zhu, Q; Zhu, Y | 1 |
| Gong, QH; Liu, XH; Pan, LL; Zhu, YZ | 1 |
| Duan, JL; Liu, CH; Liu, Y; Ma, K; Tan, BK; Zhu, Q; Zhu, YZ | 1 |
| Cai, W; Liu, H; Ma, G; Xu, J; Zhang, J; Zhang, P; Zheng, Y; Zhu, Q; Zhu, Y | 1 |
| Gong, QH; Liu, XH; Pan, LL; Yang, HB; Zheng, HM; Zhu, YZ | 1 |
| Ang, AD; Bhatia, M; Hegde, A; Sidhapuriwala, JN; Zhu, YZ | 1 |
| Cai, WM; Ma, G; Shen, HX; Tan, B; Xu, JL; Yang, P; Zhang, JL; Zheng, YT; Zhu, JH; Zhu, Q; Zhu, YZ | 1 |
| Huang, C; Kan, J; Liu, X; Ma, F; Tran, BH; Wang, S; Zhu, YZ; Zou, Y | 1 |
| Bao, G; Guo, W; Huang, C; Kan, J; Zhu, Y; Zhu, YZ | 1 |
| Guo, W; Liang, YH; Shen, YQ; Zhu, YZ | 1 |
| Bao, X; Bu, F; Cai, W; Huang, W; Liu, H; Ma, G; Shi, Q; Wang, F; Zhang, L; Zhang, P; Zhang, Y; Zheng, Y; Zhou, N; Zhu, Y | 1 |
| Luo, S; Mao, Y; Tan, B; Yang, H; Zhu, Y | 1 |
| Cheng, J; Wang, W; Zhu, Y | 1 |
| Wen, YD; Zhu, YZ | 1 |
| Huang, C; Lin, S; Liu, H; Liu, X; Tran, BH; Wang, S; Zhang, Q; Zhu, YZ | 1 |
| Ge, R; Li, X; Luo, S; Ma, F; Qian, X; Zhu, Y | 1 |
| Chen, SY; Guo, W; Kan, JT; Lin, SZ; Wang, ZJ; Wu, J; Zhu, YZ | 1 |
| Tang, W; Wang, M; Xin, H; Zhu, YZ | 1 |
| Jia, WW; Liu, L; Liu, XH; Pan, LL; Shen, XY; Wu, WJ; Yang, D; Zhang, QY; Zhu, YZ | 1 |
| Chang, L; Dai, T; Jia, W; Le, VM; Mao, Y; Rose, P; Tan, B; Tran, BH; Wang, Z; Xiong, Y; Yu, Y; Zhang, W; Zhong, R; Zhu, YZ | 1 |
1 review(s) available for cysteine and s-propargylcysteine
| Article | Year |
|---|---|
The Pharmacological Effects of S-Propargyl-Cysteine, a Novel Endogenous H2S-Producing Compound.
Topics: Animals; Chemistry, Pharmaceutical; Cysteine; Heart Failure; Humans; Hydrogen Sulfide; Myocardial Ischemia; Neovascularization, Physiologic | 2015 |
21 other study(ies) available for cysteine and s-propargylcysteine
| Article | Year |
|---|---|
S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway.
Topics: Animals; Animals, Newborn; Cell Hypoxia; Cell Survival; Cystathionine gamma-Lyase; Cysteine; Disease Models, Animal; Hydrogen Sulfide; Male; Myocardial Infarction; Myocardial Ischemia; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Up-Regulation | 2009 |
S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-κB pathway in rats.
Topics: Amyloid beta-Protein Precursor; Animals; Blotting, Western; Cysteine; Hippocampus; Hydrogen Sulfide; I-kappa B Proteins; Learning Disabilities; Lipopolysaccharides; Male; Maze Learning; Memory Disorders; NF-kappa B; Phosphorylation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; TNF Receptor-Associated Factor 1; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2011 |
Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies.
Topics: Administration, Oral; Animals; Biological Availability; Cardiotonic Agents; Chromatography, High Pressure Liquid; Cysteine; Drug Evaluation, Preclinical; Female; Injections, Intravenous; Limit of Detection; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
S-Propargyl-cysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfide-dependent mechanism.
Topics: Animals; Cell Line; Cysteine; Hydrogen Sulfide; Inflammation; Lipopolysaccharides; Myocytes, Cardiac; Rats | 2011 |
H2S donor, S-propargyl-cysteine, increases CSE in SGC-7901 and cancer-induced mice: evidence for a novel anti-cancer effect of endogenous H2S?
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cystathionine gamma-Lyase; Cysteine; Flow Cytometry; Humans; Hydrogen Sulfide; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Polymerase Chain Reaction; Stomach Neoplasms; Wound Healing | 2011 |
Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs.
Topics: Administration, Oral; Animals; Biological Availability; Cardiotonic Agents; Chromatography, Liquid; Cysteine; Dogs; Dose-Response Relationship, Drug; Female; Injections, Intravenous; Male; Mass Spectrometry; Reproducibility of Results; Time Factors | 2012 |
S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuated tumor necrosis factor-α-induced inflammatory signaling and dysfunction in endothelial cells.
Topics: Atherosclerosis; Cysteine; Endothelial Cells; Garlic; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Sulfide; Signal Transduction; Tumor Necrosis Factor-alpha; U937 Cells; Vasculitis | 2012 |
Effects of S-propargyl-cysteine (SPRC) in caerulein-induced acute pancreatitis in mice.
Topics: Acute Disease; Amylases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ceruletide; Cysteine; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gases; Hydrogen Sulfide; Inflammation; Lung; Male; Mice; Pancreas; Pancreatitis; Peroxidase; Time Factors | 2012 |
Preclinical assessment of the distribution, metabolism, and excretion of S-propargyl-cysteine, a novel H2S donor, in Sprague-Dawley rats.
Topics: Animals; Bile; Blood Proteins; Cysteine; Dogs; Feces; Female; Humans; Hydrogen Sulfide; Male; Protein Binding; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2012 |
Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cysteine; Delayed-Action Preparations; Disease Models, Animal; Fibrosis; Heart Failure; Heart Ventricles; Hydrogen Sulfide; Male; Oxidative Stress; Rats | 2013 |
S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inducing Agents; Animals; Cell Adhesion; Cell Movement; Cell Proliferation; Cysteine; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Sulfide; Male; Mice; Myocardial Ischemia; Neovascularization, Pathologic; Neovascularization, Physiologic; Protein Binding; Protein Transport; Rats; STAT3 Transcription Factor; Transcriptional Activation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
SPRC protects hypoxia and re-oxygenation injury by improving rat cardiac contractile function and intracellular calcium handling.
Topics: Animals; Apoptosis; Calcium; Cell Hypoxia; Cell Shape; Cells, Cultured; Cysteine; Intracellular Space; Male; Myocytes, Cardiac; Oxygen; Papillary Muscles; Protective Agents; Rats; Rats, Sprague-Dawley | 2014 |
Physicochemical characteristics and gastrointestinal absorption behaviors of S-propargyl-cysteine, a potential new drug candidate for cardiovascular protection and antitumor treatment.
Topics: Animals; Antineoplastic Agents; Cardiovascular System; Chemical Phenomena; Chromatography, High Pressure Liquid; Cysteine; Gastrointestinal Absorption; Hydrogen-Ion Concentration; Male; Models, Animal; Permeability; Rats, Sprague-Dawley; Solubility; Tandem Mass Spectrometry | 2015 |
The protective effects of endogenous hydrogen sulfide modulator, S-propargyl-cysteine, on high glucose-induced apoptosis in cardiomyocytes: A novel mechanism mediated by the activation of Nrf2.
Topics: Animals; Antioxidants; Apoptosis; Blood Glucose; Cell Line; Cystathionine gamma-Lyase; Cysteine; Cytoprotection; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression Regulation; Hydrogen Sulfide; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Male; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA Interference; Signal Transduction; Time Factors; Transfection; Up-Regulation | 2015 |
The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Female; G2 Phase Cell Cycle Checkpoints; Garlic; Humans; JNK Mitogen-Activated Protein Kinases; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphorylation; Phytotherapy; Plants, Medicinal; Proteolysis; RNA Interference; Signal Transduction; Time Factors; Transfection; Ubiquitination; Xenograft Model Antitumor Assays | 2015 |
Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiotonic Agents; Creatine Kinase; Cysteine; Delayed-Action Preparations; Electrocardiography; Glutathione; Hydrogen Sulfide; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Myocardial Infarction; Rats, Sprague-Dawley; Superoxide Dismutase | 2015 |
Novel hydrogen sulfide-releasing compound, S-propargyl-cysteine, prevents STZ-induced diabetic nephropathy.
Topics: Animals; Cell Proliferation; Cell Size; Cells, Cultured; Cysteine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Extracellular Matrix; Hydrogen Sulfide; Kidney; Male; MAP Kinase Signaling System; Mesangial Cells; Nephritis; Rats, Sprague-Dawley; Smad3 Protein; Transforming Growth Factor beta1 | 2016 |
Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity.
Topics: Animals; Calcium; Cardiotoxicity; Cell Nucleus; Cysteine; Cytokine Receptor gp130; Doxorubicin; Hydrogen Sulfide; Male; Mice, Inbred C57BL; Mitochondria; Models, Biological; Myocytes, Cardiac; Phosphorylation; Protein Transport; Rats; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor | 2016 |
S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway.
Topics: Anemia; Animals; Cysteine; Disease Models, Animal; Hepcidins; Hydrogen Sulfide; Inflammation; Interleukin-6; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Signal Transduction; STAT3 Transcription Factor | 2016 |
S-propargyl-cysteine attenuates inflammatory response in rheumatoid arthritis by modulating the Nrf2-ARE signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidant Response Elements; Arthritis, Rheumatoid; Cell Line; Cell Movement; Cell Survival; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; NF-E2-Related Factor 2; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Up-Regulation | 2016 |
A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway.
Topics: Animals; Antioxidants; Cardiotonic Agents; Cystathionine gamma-Lyase; Cysteine; Disease Models, Animal; Fibrosis; Heart Failure; Hydrogen Sulfide; Liposomes; Male; Myocardium; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2019 |